Thirumalai Chemicals ICRA cut: BBB (Neg) rating in 2026

What changed in the latest ICRA action

Thirumalai Chemicals Limited (NSE: TIRUMALCHM | BSE: 500412) informed exchanges that ICRA has downgraded all its rated debt facilities. The long-term rating moved down from BBB+ to BBB with a Negative outlook. The short-term rating was revised from A2 to A3+. Alongside the downgrade, ICRA also increased the total rated amount to ₹1,404.50 crore.

The key reason: US plant cost overrun and timeline shift

The company attributed the rating pressure to a cost overrun and delay at its new plant in the United States. The disclosed cost overrun stands at USD 340 million. The commissioning timeline has also shifted, with the plant now slated for December 2026. The update matters because the delay and higher costs have required additional borrowing. And that has tightened liquidity, which was cited as a core driver behind the downgrade.

What the new ratings mean, in plain terms

A downgrade typically signals that the rating agency sees higher credit risk than before, based on the information reviewed. In this case, ICRA’s long-term rating is now BBB with a Negative outlook, indicating ongoing downside risk. The short-term rating moving to A3+ similarly reflects weaker near-term comfort compared with the earlier A2. The company’s disclosure framed the downgrade as linked to incremental borrowings and stretched liquidity due to the US project.

Rated amount increased to ₹1,404.50 crore

One of the most concrete changes in the exchange disclosure is the enhancement of the overall rated amount to ₹1,404.50 crore. This suggests more facilities or higher limits have come under ICRA’s rating coverage compared with earlier actions referenced by the company. The disclosure does not break out the facility-wise increase in this update. But it clearly ties the enhanced rated amount to the broader borrowing needs arising from the project overrun and delay.

Earlier ICRA reviews referenced in the disclosure

The provided material also refers to earlier ICRA actions around Thirumalai Chemicals’ credit profile. It notes that ICRA reviewed the company following FY2026 results for the year ended March 31, 2026. The FY2026 results were released on May 30, 2026, and a rating action date of June 9, 2026 is referenced for a Negative outlook assignment on long-term debt instruments totaling ₹1,217.55 crore. Separately, an earlier January 2026 communication is also cited, where multiple instruments totaling ₹1,317.55 crore were rated at BBB+ (Negative) for long-term and A2 for short-term facilities.

Summary table: ratings and key amounts mentioned

Timeline and earlier rating references

Market impact: what investors and lenders typically track

Credit rating changes can influence borrowing costs, lender appetite, and covenant headroom, especially when outlooks turn Negative. The company’s update links the downgrade directly to higher borrowing and liquidity stretch, implying financing has become a central point of monitoring. The US project timeline being pushed to December 2026 also extends the period during which cash flows may not fully reflect the new capacity, based on the disclosure’s logic. While the announcement does not quantify interest cost impact or stock reaction, it gives investors a clear set of variables to watch: project execution, funding needs, and liquidity.

Why this matters: linking project execution to credit quality

The disclosed USD 340 million overrun is significant because it changes the funding requirement of the project and raises the need for external capital. When a large project slips, it can create a mismatch between scheduled debt servicing and the expected operational ramp-up. The enhanced rated amount to ₹1,404.50 crore adds another layer, as more borrowings are now within rated facilities. ICRA’s downgrade and Negative outlook, as described, reflects the agency’s concern that these conditions could persist without improvement in liquidity.

What to watch next

The company has already identified December 2026 as the updated commissioning target for the US plant. Future rating outcomes will likely depend on progress against that timeline and the trajectory of borrowings and liquidity, as implied by the rationale described in the disclosure. Any further exchange updates tied to financing arrangements or project milestones will be important reference points. For now, the confirmed facts are the rating downgrade to BBB (Negative) and A3+, the rated amount enhanced to ₹1,404.50 crore, and the project cost and timing pressures cited as the trigger.